Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) and Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.
Profitability
This table compares Galmed Pharmaceuticals and Esperion Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Galmed Pharmaceuticals | N/A | -20.37% | -18.16% |
| Esperion Therapeutics | -3.66% | N/A | -3.93% |
Institutional & Insider Ownership
76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Comparatively, 1.7% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Galmed Pharmaceuticals | N/A | N/A | -$7.52 million | ($0.32) | -1.97 |
| Esperion Therapeutics | $403.14 million | 1.55 | -$51.74 million | ($0.17) | -14.35 |
Galmed Pharmaceuticals has higher earnings, but lower revenue than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Galmed Pharmaceuticals has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations for Galmed Pharmaceuticals and Esperion Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Galmed Pharmaceuticals | 1 | 1 | 0 | 0 | 1.50 |
| Esperion Therapeutics | 1 | 1 | 5 | 1 | 2.75 |
Esperion Therapeutics has a consensus target price of $7.60, suggesting a potential upside of 211.48%. Given Esperion Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Esperion Therapeutics is more favorable than Galmed Pharmaceuticals.
Summary
Esperion Therapeutics beats Galmed Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
About Esperion Therapeutics
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
